The psychometric properties of the King&apos;s Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.

doi: 10.1016/S2213-2600(20)30036-9.

RECOMMENDED

Interstitial Lung Disease

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V

doi: 10.1016/S2213-2600(19)30341-8.

RECOMMENDED

Lung Cancer

Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study

★ 1 Recommended by Dr Martin Frey, Faculty Member

doi: 10.1016/S1470-2045(20)30093-0.

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

Eur Respir J.

Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M

doi: 10.1183/13993003.00161-2019.

RECOMMENDED

Interstitial Lung Disease

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

doi: 10.1016/j.chest.2020.03.037.

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

N Engl J Med.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD Trial Investigators.

doi: 10.1056/NEJMoa1908681.

RECOMMENDED

Interstitial Lung Disease

Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Med

Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T

doi: 10.1016/j.rmed.2021.106574

RECOMMENDED

EmphysemaInterstitial Lung DiseasePulmonary Fibrosis

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study)

Eur Respir J.

Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V

doi: 10.1183/13993003.02718-2020.

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Progression of fibrosing interstitial lung disease

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res.

Wong AW, Ryerson CJ, Guler SA

doi: 10.1186/s12931-020-1296-3.

Pneumology

The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases

Related content

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study)

Progression of fibrosing interstitial lung disease